"GMA" and sponsor Insmed explore life with a rare chronic condition that affects around 500,000 Americans, leaving them unable to do the things they love.

Until recently, there were no treatments designed specifically for bronchiectasis. Now, landmark research by Professor James Chalmers has discovered the world’s first potential therapy for the disease...

Now is the time to help shape the next decade of lung health in the NHS. Ask your MP to write to Wes Streeting and urge him to prioritise lung health in the new NHS 10-Year Plan. Urgent action is…

The number of people making five or more emergency visits to hospital a year with lung difficulties has almost tripled in some parts of England, an analysis has found. The charity Asthma + Lung UK sa...

An online magazine to support people with COPD to self-manage their symptoms, embedding guidance, infographics and links to videos our expert team has curated to educate, motivate and inspire.

BackgroundMacrolide maintenance therapy (MMT) has demonstrated notable efficacy in reducing exacerbation in patients with bronchiectasis, which is a major risk factor for cardiovascular events. However, a comprehensive assessment of the cardiovascular benefits and safety profile of MMT in this population is lacking.MethodsThis territory-wide cohort study analyzed patients diagnosed with bronchiectasis in Hong Kong between 2001 and 2018. Patients were classified as MMT receivers or macrolide non-receivers based on the administration of MMT. Propensity score (PS) matching was employed for confounding factors adjustment. The primary outcome of interest was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction and stroke. The safety outcome was the occurrence of ventricular arrhythmias or sudden cardiac death. Cox proportional hazard regression analysis was utilized to compare the incidence of outcomes across the two groups.ResultsA total of 22 895 patients with bronchiectasis were identified. Following 1:2 PS matching, the final cohort consisted of 3137 individuals, with 1123 MMT receivers and 2014 macrolide non-receivers. MMT administration was associated with a significant reduced risk of MACE (16.38 versus 24.11 events per 1000 person years; HR 0.68; 95% CI 0.52–0.90). Importantly, the use of MMT was not associated with elevated risk of ventricular arrhythmias or sudden cardiac death (7.17 versus 7.67 events per 1000 person years; HR 0.93; 95% CI 0.60–1.44).ConclusionsThe administration of MMT in patients with bronchiectasis was associated with a significant reduction in the risk of MACE, without any evidence suggesting an increased risk of severe arrhythmia-related adverse events.